- Home
- PTHL vs AVTX Comparison
PTHL vs AVTX Comparison
Compare PTHL & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- AVTX
- Stock Information
- Founded
- PTHL 1998
- AVTX 2011
- Country
- PTHL China
- AVTX United States
- Employees
- PTHL N/A
- AVTX N/A
- Industry
- PTHL
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- PTHL
- AVTX Health Care
- Exchange
- PTHL Nasdaq
- AVTX Nasdaq
- Market Cap
- PTHL 85.4M
- AVTX 90.0M
- IPO Year
- PTHL 2024
- AVTX 2015
- Fundamental
- Price
- PTHL $0.63
- AVTX $9.02
- Analyst Decision
- PTHL
- AVTX Strong Buy
- Analyst Count
- PTHL 0
- AVTX 8
- Target Price
- PTHL N/A
- AVTX $31.00
- AVG Volume (30 Days)
- PTHL 3.5M
- AVTX 318.1K
- Earning Date
- PTHL 01-01-0001
- AVTX 08-07-2025
- Dividend Yield
- PTHL N/A
- AVTX N/A
- EPS Growth
- PTHL N/A
- AVTX N/A
- EPS
- PTHL N/A
- AVTX N/A
- Revenue
- PTHL $448,196.00
- AVTX $441,000.00
- Revenue This Year
- PTHL N/A
- AVTX N/A
- Revenue Next Year
- PTHL N/A
- AVTX N/A
- P/E Ratio
- PTHL N/A
- AVTX N/A
- Revenue Growth
- PTHL N/A
- AVTX N/A
- 52 Week Low
- PTHL $0.60
- AVTX $3.39
- 52 Week High
- PTHL $32.00
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- PTHL N/A
- AVTX 71.44
- Support Level
- PTHL N/A
- AVTX $8.59
- Resistance Level
- PTHL N/A
- AVTX $9.88
- Average True Range (ATR)
- PTHL 0.00
- AVTX 0.99
- MACD
- PTHL 0.00
- AVTX 0.05
- Stochastic Oscillator
- PTHL 0.00
- AVTX 76.57
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).